NCT00587691已完成1 期
An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 4
- 主要终点
- Evaluation of safety and tolerability
研究概览
简要总结
The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.
详细描述
The principle of TCV is similar to that of traditional microbial vaccination where attenuated infectious agents are used to stimulate protective immune responses. Because pathogentic autoreactive T cells are viewed as pathogens in T cell-mediated autoimmune diseases, they can be used, as a vaccine to prevent and treat the diseases in which they are able to induce.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stable MS disease within 30 days prior to enrollment
- •EDSS Score between 2 and 8 inclusively
- •Failed to respond to or cannot tolerate at least 1 or more of the currently approved drugs for MS.
排除标准
- •Women who are pregnant or breast-feeding or who plan to become pregnant during the study
- •Has taken immunomodulating drugs within 60 days prior to screening
- •HIV positive
结局指标
主要结局
Evaluation of safety and tolerability
时间窗: Yearly Intervals
次要结局
- To assess changes in EDSS Scores(Yearly Intervals)
- To assess changes in the frequency of MS relapses(Yearly Intervals)
- To assess changes in the myelin-reactive profile in the blood(Yearly Intervals)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAARTHuman Immunodeficiency Virus (HIV)NCT02225665Sangamo Therapeutics8
已完成
1 期
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid TumorsTumorsNCT00422682Sanofi136
已完成
1 期
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)Relapsed/RefractoryMultiple MyelomaNCT03439280Millennium Pharmaceuticals, Inc.50
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid TumorsNeoplasmsNCT01562275Genentech, Inc.67
已完成
1 期
Study of TAK-901 in Adults With Advanced Solid Tumors or LymphomaAdvanced Solid TumorsLymphomaNCT00935844Millennium Pharmaceuticals, Inc.20